تحلیل روند مصرف و پیش بینی آینده بازار داروهای قلبی- عروقی در ایران

Background and Aim: Variety in the pharmaceutical products and therapeutic groups, development of new pharmaceutical products and heavy costs in the pharmaceutical marketing, force the firms to attend in the specific area, related products and defined basket in order to decrease high marketing costs and act highly and accurately in the target market, costumer recognition and competitor analysis. To do this, market of cardiovascular disease as the most important parts of the pharmaceutical marketing has been evaluated during 15 years. Materials and Methods: To do this, sale's statistics of 29 cardiovascular drugs were collected from official Iran drug list through 15 years. Then in order to forecast the consumption of each category, linear regression was used. A correlation between variables was tested by Pearson correlation coefficient. Results: our results showed that Beta blockers and Nitrates from cardio drugs and Platelet aggregation inhibitors and Statins from vascular drugs have the highest consumption in comparison with other drugs. Also there is a positive correlation between total numbers of sales of cardio drugs, vascular drugs and cardiovascular drugs and middle age with correlation coefficients of 0.976, 0.979 and 0.976 and confidence interval of 95% and there is no correlation between the mentioned items and Gross domestic product. Cardiovascular drug consumption will increase by aging of the population. Gross domestic product will not affect the people payment’s ability Conclusion: Based on our results, it is better for pharmaceutical companies to pay more attention to Beta blockers and Nitrates from cardio drugs and Platelet aggregation inhibitors and Statins from vascular drugs in order to decrease high marketing costs and act highly and accurately in the target market.